Introduction
Alzheimer's disease (AD), a neurodegenerative disease, is characterized by extensive deposition of amyloid β (Aβ) called amyloid plaque and formation of neurofibrillary tangles (NFTs). Aβ has been long thought to be the most causative factor in AD, and therefore, a variety of AD drugs targeting Aβ have been developed. No beneficial result, however, has been obtained even though Aβ was cleaned up from the brain. A current challenge, therefore, has focused upon Tau protein.
Tau, a microtubule-associated protein, is abundantly expressed in neurons of the central nervous system. Tau is upregulated during neuronal development, to promote generation of cell processes and establish cell polarity [1] . Microtubules are the tracks for motor proteins bearing intracellular cargo transport [2, 3] . Tau polymerizes and stabilizes microtubules by interacting with tubulin, and modulates microtubule dynamics including axonal transport [4] [5] [6] [7] .
When hyperphosphorylated, Tau detaches from the microtubules and forms insoluble fibrils, referred to as paired helical filaments (PHFs), followed by NFTs comprising aggregation of PHFs [8, 9] . Aggregation of hyperphosphorylated Tau is responsible for tauopathies, a class of neurodegenerative diseases, that include not only AD but frontotemporal dementia and parkinsonism linked to chromosome 17, progressive supranuclear palsy, Pick's disease, and corticobasal degeneration [10] .
Tau is phosphorylated by serine/threonine protein kinases such as GSK-3β, cyclin-dependent kinase 5 (Cdk5)/p25, extracellular signal-regulated kinase 2 (ERK2), p70 ribosomal protein S6 kinase (p70-S6K), microtubule affinity-regulating kinase (MARK), SAD kinase (SADK), protein kinase A (PKA), calcium/calmodulin-dependent protein kinase II (CaMKII) or tyrosine kinases such as Fyn and c-Abl [11] [12] [13] [14] [15] . Of the protein kinases GSK-3β plays a central role in Tau phosphorylation relevant to tauopathies. The present review shows that the linoleic acid derivative DCP-LA is capable of preventing Tau phosphorylation by targeting GSK-3β.
Tau phosphorylation in the AD brain
Tau from the AD brain contains eleven Ser/Thr-Pro sites, that are phosphorylated by proline-directed kinases, and nine Ser/Thr-X sites, that are phosphorylated by non-proline-directed kinases.
GSK-3β, Cdk5/p25, ERK2, and p70-S6K belong to proline-directed kinases, which phosphorylate Tau at Thr181, Ser202/T205, Thr212/S214,
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Thr231/Ser235, and Ser396/Ser404 on Ser-Pro or Thr-Pro motifs in the regions flanking the repeat domains [11] [12] [13] . MARK, SADK, PKA, and CaMKII belong to non-proline-directed kinases, which phosphorylate Tau at Ser262, Ser 320, Ser324, and Ser356 on KXGS motifs in the repeat domains (R1-R4) [12, 14, 15] . The non-receptor tyrosine kinases (non-RTKs) Fyn and c-Abl phosphorylate Tau at Tyr-18 and Tyr-394 [12] .
GSK-3β is enriched in the brain and preferentially expressed in the hippocampus.
GSK-3β acts as the main executioner of Tau phosphorylation in PHFs [16, 17] . Intriguingly, GSK-3 accelerates the rate of Tau phosphorylation several-fold, if Tau is pre-phosphorylated by priming kinases such as non-proline-directed kinases [18] [19] [20] . Of Tau phosphorylation sites, Ser396 phosphorylation is a key step in the PHF formation [21] . Once a priming kinase phosphorylates Tau at Ser404, GSK-3β phosphorylates Tau at Ser400, followed by sequential phosphorylation of Ser396 [21] . GSK-3β, alternatively, phosphorylates Tau at Ser202 directly, but Thr231 phosphorylation requires for Ser235 pre-phosphorylation [21] .
Interaction between Aβ and GSK-3β
GSK-3β is originally in the active form. GSK-3β is inactivated by being phosphorylated at Ser9 and activated by being phosphorylated at Tyr216 [22] .
Aβ activates the non-RTK Fyn, that in turn, activates GSK-3β by phosphorylating at Tyr216, leading to Tau phosphorylation and accumulation in neurons [23, 24] . Aβ, alternatively, inhibits/inactivates phosphoinositide 3-kinase (PI3K), thereby suppressing GSK-3β-Ser9 phosphorylation, to activate GSK-3β [25] . Chronic exposure of Aβ downregulates Akt phosphorylation, to activate GSK-3β and increase Tau phosphorylation [26] . Soluble Aβ oligomers inhibit insulin signaling relevant to Akt activation, to activate GSK-3β and increase
Tau phosphorylation [27] . Intracellular Aβ1-42 promotes Tau phosphorylation and induces neuronal loss [28] . GSK-3β exacerbates Aβ-induced neurotoxicity and cell death [29] .
Amyloid precursor protein (APP) intracellular domain (AICD), that is produced from -secretase-mediated APP cleavage, activates GSK-3β [30] or enters the nucleus and activates gene transcription, increasing the GSK-3β mRNA and protein [31] . C-terminal fragments of APP stimulate GSK-3β activation, to increase Tau phosphorylation and induce apoptosis [32] .
Aging, inflammation, and stress also activate GSK-3β, causing an initial Tau phosphorylation, responsible for mild cognitive impairment (MCI), a preliminary group of AD.
Aβ further activates GSK-3β and accelerates Tau phosphorylation, leading to progression into AD from MCI [33, 34] .
Regulation of GSK-3β activity
The serine/threonine protein kinases such as PKC [35] , Akt [35] , PKA [36] , integrin-linked kinase (ILK) [37] , CaMKII [38] , p90 ribosomal protein S6 kinase (p90RSK) [39] , and cGMP-dependent protein kinase 1 (PrkG1) [40] inactivate GSK-3β by directly phosphorylating at Ser9 (Figure 1 ). Conversely, inhibition of those kinases allows relative activation of GSK-3β.
Pyk2 binds to and activates SH2 and SH3 domain-containing proteins like Src kinases.
Pyk2 and Fyn activate GSK-3β by phosphorylating at Tyr216 directly [23, 41] (Figure 1 ).
Akt1 is activated by being phosphorylated at Thr308 and Ser473 through the major pathway along a RTK/insulin receptor substrate 1 (IRS-1)/PI3K/3-phosphoinositide-dependent protein kinase 1 (PDK1)/Akt axis, to phosphorylate GSK-3β at Ser9 and inactivate GSK-3β [35] ( Figure 2 ). Accordingly, activation of RTK induces inactivation of GSK-3β; conversely, inhibition of RTK induces activation of GSK-3β. For example, insulin or insulin-like growth-factor 1 (IGF1) binds to and activates the RTK insulin receptor involving GSK-3β inactivation, which occurs still in the brain.
Lines of evidence have pointed to other pathways for regulation of GSK-3β activity.
AMP-activated protein kinase (AMPK) phosphorylates and inactivates GSK-3β [42] , while AMPK by itself phosphorylates Tau at Ser262 [43] . Aβ1-42 upregulates expression of adenylate kinase-1 (AK1), that inhibits AMPK, causing GSK-3β activation [43] . AMPK is activated due to inhibition of protein phosphatase 2A (PP2A) through a sphingosine-1-phosphate receptor 1 (S1PR1) linked to Gi protein [44] , thereby inactivating GSK-3β. 
Linoleic acid derivative DCP-LA
PKC is classified into the conventional PKC isozymes , I, II, and , the novel PKC isozymes , , , and , the atypical PKC isozymes / and , and the PKC-like isozymes and .
All the PKCs have the phosphatidylserine (PS) binding site and are activated by diacylglycerol (DG) [45] . Of the PKC isozymes cis-unsaturated free fatty acids (uFFAs) such as arachidonic, linoleic, linolenic, oleic, and docosahexaenoic acid directly interact with the novel PKC isozymes [45] . uFFAs are very unstable, and therefore, we have originally synthesized the
with cyclopropane rings instead of cis-double bonds, that exhibits stable bioactivities [46] .
The primary site of action of DCP-LA is PKC . DCP-LA activates PKC selectively and directly still in the absence of DG and calcium [47] . DCP-LA binds to the PS binding/associating sites Arg50 and Ile89 in the C2-like domain of PKC at the carboxyl-terminal end and the cyclopropane rings, respectively, which are distinct from the phorbol 12-myristate 13-acetate (PMA) binding site in the C1 domain [48] (Figure 3) .
DCP-LA, on the other hand, acts as a potent inhibitor of protein tyrosine phosphatase 1B (PTP1B) through its direct interaction [49] . 
DCP-LA inactivates GSK-3β by cooperation of PKC activation and PTP1B inhibition
PKC , activated by DCP-LA, inactivates GSK-3β by directly phosphorylating at Ser9 (Figure 4 ) [35] . Activated PKC , alternatively, activates Akt by directly phosphorylating at the serine residue, followed by inactivation of GSK-3β [35] (Figure 4 ). PKC activation or PTP1B inhibition is capable of inactivating GSK-3β each independently. In experiments using PC-12 cells, PKC overexpression and PTP1B deficiency activate Akt and inactivate GSK-3β synergistically [35] . This indicates that DCP-LA enables more efficient inactivation of GSK-3β by cooperation of PKC activation and PTP1B inhibition [35] (Figure 4) . 
DCP-LA prevents Tau phosphorylation by targeting GSK-3β
Aβ1-42 activates GSK-3β by reducing GSK-3β-Ser9 phosphorylation, leading to an enhancement in the Tau phosphorylation at Ser202/Thr205 and Ser396, and the Aβ1-42-induced Tau phosphorylation is neutralized by DCP-LA [35] . This indicates that DCP-LA prevents Tau phosphorylation by inactivating GSK-3β with PKC activation and PTP1B inhibition.
5xFAD mouse, as an animal model of AD, is APP/presenilin 1 (PS1) double transgenic mice that coexpress five familial forms of AD mutations such as the Swedish/London/Florida mutations and the M146L/L286V mutations [50] . The Aβ1-42 levels in the 5xFAD mouse brain rise in an age-dependent manner [50] . The GSK-3β activity is enhanced in parallel with Aβ1-42 rise and Tau-Ser396 phosphorylation, responsible for PHF formation, is accelerated in the hippocampus of 5xFAD mice [51] . DCP-LA suppresses the GSK-3β activation and Tau-Ser396 phosphorylation in the hippocampus of 5xFAD mice [35] . DCP-LA, thus, has the potential to restrain Tau-Ser396 hyperphosphorylation efficiently by activating PKC and inhibiting PTP1B simultaneously.
DCP-LA ameliorates cognitive disorders by facilitating hippocampal synaptic transmission
Tau hyperphosphorylation causes tauopathies. Cognitive decline in association with tauopathies including AD, however, could not be improved only by suppression of Tau phosphorylation.
DCP-LA promotes vesicular transport of 7 ACh receptor towards the cell surface in a PKC -dependent manner [52, 53] . DCP-LA-induced increase in 7 ACh receptor on the plasma membrane at presynaptic terminals stimulates presynaptic glutamate release [52, 54] . DCP-LA, alternatively, promotes exocytosis of -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, a major postsynaptic excitatory receptor, through CaMKII activation due to PP-1 inhibition [55] . Those effects of DCP-LA on 7 ACh receptor and AMPA receptor induce a long-lasting facilitation of hippocampal synaptic transmission, to enhance cognitive functions [46, 56] .
Indeed, DCP-LA ameliorates spatial learning and memory decline in 5xFAD mice [35] .
Moreover, DCP-LA improves Aβ1-40-and mutant Aβ-induced spatial learning deficits in rats [57, 58] , scopolamine-induced spatial learning and memory impairment in rats [57] , spatial learning and memory deterioration in senescence accelerated mice [59, 60] . Overall, DCP-LA could improve cognitive disorders in a variety of dementias.
Interestingly, DCP-LA protects neurons from oxidative stress-induced apoptosis by inhibiting caspase-3/-9 activation [61]. This indicates that DCP-LA could also prevent progression of neuronal loss in the AD brain.
Conclusions
9 DCP-LA restrains Tau phosphorylation efficiently due to PKC -mediated direct inactivation of GSK-3β, to PKC /Akt-mediated inactivation of GSK-3β, and to RTK/IRS-1/PI3K/PDK1/Akt-mediated inactivation of GSK-3β in association with PTP1B
inhibition. In addition, DCP-LA induces a long-lasting facilitation of hippocampal synaptic transmission, to enhance cognitive functions. Taken together, DCP-LA could not only prevent Tau phosphorylation but improve cognitive impairments associated with tauopathies.
Consequently, DCP-LA could be developed as a promising drug for prevention and therapy of tauopathies. 
